A Randomized Controlled Trial Comparing the Effectiveness of Different Treatment Options for Weight Management After Discontinuation of Semaglutide and Tirzepatide (GLP1 Transition Trial)
Completed · Phase 4
Conditions studied: Obesity, Overweight
In brief
The study compares the effectiveness of treatment options for weight management after discontinuing semaglutide and tirzepatide. The primary outcome is absolute and percentage weight change at 12-weeks.
Key facts
- Study ID
- NCT06605703
- Run by
- WW International Inc
- People needed
- 226
- Starts
- 2024-09-18
- Expected to finish
- 2026-02-05
- Last updated by the study team
- 2026-04-13
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- 18 years or older
- Previous hx of BMI of >30 or BMI of >27 with one or more weight related medically qualifying condition (hypertension, dyslipidemia, sleep apnea, cardiovascular disease)
- Currently taking Wegovy, Ozempic, Mounjaro or Zepbound and have been for at least 6 months
- At least 15% body weight loss since taking Wegovy, Ozempic, Mounjaro, or Zepbound
- Willing to stop taking their GLP-1 medication or is discontinuing due to circumstances such as access, cost, coverage, choice, or any other reason
- Ability to provide informed consent prior to any trial-related activities
- Able to read and write in English
You may not qualify if…
- BMI <22 kg/m2
- Diabetes
- Previous surgical obesity treatment
- Currently pregnant or intending to become pregnant during the study
- Breastfeeding
- History of seizures or epilepsy
- Current opioid use or in acute opioid withdrawal
- Abrupt discontinuation of alcohol, benzodiazepines, barbiturates, antiepileptic drugs
- History of glaucoma
- Uncontrolled hypertension
- Severe renal impairment and/or Chronic kidney disease stage III or GFR <60
- Acute hepatitis or liver failure
- Acute or chronic metabolic acidosis, including diabetic ketoacidosis
- Use of antipsychotic medications or opiod analgesics
- Current or previous history of anorexia or bulimia nervosa
- Engagement with vomiting or laxative use within the last 28 days with the aim of controlling their shape or weight
- Current SSRI, SNRI, mood stabilizer, amphetamine, or corticosteroid use
- Current diagnosis of hyper or hypothyroidism or current use of thyroid replacement medicine
- Current use of beta blockers
- Current use of depo shot (medroxyprogesterone acetate) for birth control
- Current diagnosis of Cushing's disease or syndrome
- Current use of Monoamine Oxidase Inhibitors (MAOIs)
- Known hypersensitivity to bupropion, naltrexone, or metformin
- Any other reason rendering a participant unsuitable for trial participation, as determined by a clinician or study investigator
Where it is running
- WW International, Inc — New York, New York, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.